Fortive Corporation has been the subject of several major investment conversations. Amid mixed analyst recommendations, \u003ca href='https://www.morganstanley.com/'\u003eMorgan Stanley\u003c/a\u003e and \u003ca href='https://www.jpmorganchase.com/'\u003eJP Morgan\u003c/a\u003e have issued a 'Hold' and 'Underweight' rating respectively for the company. Analysts are closely scrutinising Fortive's valuation and recent returns, while investors such as \u003ca href='https://www.sumintrust.com/'\u003eSumitomo Mitsui Trust Group Inc.\u003c/a\u003e and \u003ca href='https://www.nordea.com/'\u003eNordea Investment Management\u003c/a\u003e hold significant stocks. Notably, Fortive’s new CE-Marked sterilization cycle could increase its recurring revenue in healthcare. Despite a downgrade from JP Morgan, the target price was raised to $57, underscoring mixed market sentiments. \u003ca href='https://www.cnbc.com/mad-money/'\u003eJim Cramer\u003c/a\u003e of CNBC described Fortive as a “Great” company, while its spin-off, Ralliant, continues to add volatility to its stock performance. Despite decreased growth expectations and recent undervaluations, many are watching Fortive's movements closely for promising investment opportunities.
Fortive Corporation FTV News Analytics from Wed, 09 Apr 2025 07:00:00 GMT to Sat, 17 Jan 2026 19:11:47 GMT -
Rating 2
- Innovation 3
- Information 7
- Rumor -1
